
Investor Relations
Investor Relations
Corporate Profile
Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Aug 09
2022
2022
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
Learn More >
Aug 03
2022
2022
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
Learn More >
Jul 27
2022
2022
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
Learn More >
Jul 12
2022
2022
Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
Learn More >
Jun 08
2022
2022
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
Learn More >
May 19
2022
2022
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Learn More >
May 09
2022
2022
Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal
Learn More >
May 04
2022
2022
Allogene Therapeutics Reports First Quarter 2022 Financial Results
Learn More >
Apr 28
2022
2022
Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
Learn More >
Apr 27
2022
2022